286 related articles for article (PubMed ID: 18159717)
1. [Treatment guideline for breast cancer and SERM-treatment].
Iwase H; Yamamoto Y; Kawasoe T
Nihon Rinsho; 2007 Nov; 65 Suppl 9():636-40. PubMed ID: 18159717
[No Abstract] [Full Text] [Related]
2. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
3. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
5. [Additional effect of SERM: mammary gland].
Kurebayashi J
Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
[TBL] [Abstract][Full Text] [Related]
6. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
7. [Breast neoplasms: predictive factors for endocrine therapy ].
Hayashi S
Nihon Rinsho; 2007 Jun; 65 Suppl 6():148-53. PubMed ID: 17682151
[No Abstract] [Full Text] [Related]
8. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
9. A 62-year-old woman with a new diagnosis of breast cancer.
Come SE
JAMA; 2006 Mar; 295(12):1434-42. PubMed ID: 16551716
[No Abstract] [Full Text] [Related]
10. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
11. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
Ito Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
[No Abstract] [Full Text] [Related]
12. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
13. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors in breast cancer: an overview.
Altundag K; Ibrahim NK
Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
[TBL] [Abstract][Full Text] [Related]
16. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
17. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Fentiman IS
Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
19. [Future endocrine therapy of breast cancer].
Ejlertsen B
Ugeskr Laeger; 2007 Jan; 169(4):296. PubMed ID: 17274921
[No Abstract] [Full Text] [Related]
20. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
Dediu M; Median D; Alexandru A; Vremes G; Gal C; Gongu M
J BUON; 2009; 14(3):375-9. PubMed ID: 19810126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
